DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Tuesday. The firm issued a hold rating on the stock.

DBVT has been the topic of several other research reports. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright upped their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Trading Down 3.0 %

Shares of DBV Technologies stock opened at $0.78 on Tuesday. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.17. The firm has a market capitalization of $75.11 million, a P/E ratio of -0.93 and a beta of 0.67. The business has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.94.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The business had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. During the same period in the previous year, the firm earned ($0.26) EPS. Analysts predict that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. raised its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the period. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.